NASDAQ Companies

FOSTER CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) — Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a clinical-stage biopharmaceutical […]

BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the […]

PRINCETON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD) today announced that Bradley Campbell, President and Chief […]

Topline data from LIFT-AD on track for second half of 2024 Previously reported independent, unblinded interim analysis supports trial continuation […]

Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team Reports […]

– In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose-Dependent Splicing Correction, Muscle Delivery and DMPK Knockdown – – All Evaluable […]

MANNHEIM, Germany, Jan. 03, 2024 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company […]

TEL AVIV, Israel, Jan. 03, 2024 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application […]

Seoul, Jan. 03, 2024 (GLOBE NEWSWIRE) — GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and publisher of […]

The confirmatory clinical, safety and efficacy study for AVT06, biosimilar candidate to Eylea® (aflibercept) met its primary endpoint in patients […]